Simulations Plus, Inc.(SLP)Earnings, Financials & Key Ratios

SAN DIEGO, July 6, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws. On April 3, 2025, Simulations Plus reported second-quarter fiscal 2025 financial results and maintained full-year revenue guidance of $90 million to $93 million.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that helps advance biopharma innovation, today announced it is building the agentic layer of Composer, its AI-native platform for model-informed drug development, using the NVIDIA BioNeMo Agent Toolkit. The initiative expands the companies' collaboration announced in May 2026, extending their work in GPU-.